Combined Inhibition of Bcl2 and Bcr-Abl1 Exercises Anti-Leukemia Activity but Does Not Eradicate the Primitive Leukemic Cells.
Michele MassiminoPaolo VigneriStefania StellaElena TirròMaria Stella PennisiLaura Nunziatina ParrinelloCalogero VetroLivia ManzellaFabio StagnoFrancesco Di RaimondoPublished in: Journal of clinical medicine (2021)
Our results suggest that primitive CML leukemic cells are not dependent on BCL2 for their persistence and support that committed CML and Ph + ALL cells are dependent by BCL2 and BCR-ABL1 cooperation for their survival. The antileukemic activity of BCL2 and BCR-ABL1 dual targeting may be a useful therapeutic strategy for Ph+ ALL patients.
Keyphrases
- chronic myeloid leukemia
- tyrosine kinase
- induced apoptosis
- cell cycle arrest
- acute lymphoblastic leukemia
- acute myeloid leukemia
- endoplasmic reticulum stress
- end stage renal disease
- bone marrow
- chronic kidney disease
- cell death
- prognostic factors
- newly diagnosed
- signaling pathway
- cell proliferation
- cancer therapy
- pi k akt